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DOI 10.1016/j.chembiol.2010.03.003In the U.S. or Europe, India is often asso-
ciated with information technology or
service outsourcing, not with scientific
research. Nonetheless, largely unnoticed
by western media, India has been making
strides toward becoming a research
powerhouse in the life sciences. Enjoying
unique manpower and cost advantages,
this country now has several major univer-
sities and scientific institutions with active
programs in this area. Spurred by sup-
portive government agencies, these insti-
tutions are producing an increasing num-
ber of publications, patents, and industry
spin-offs. Consider Bangalore-based
Institute of Bioinformatics (IOB), a rela-
tively small 40 member outfit that hasProteogenomics, the use of proteomics to annotate genes, is an
area where IOB has carved out a niche for itself.nonetheless become a major global
player in proteomics research. In less
than a decade of existence, the institute
has produced what is arguably the
world’s best curated protein database
and is well on its way to replicating this
success in cancer biomarkers, proteoge-
nomics, and signaling pathways. ‘‘We
undertake projects that most other labs
would find extremely hard,’’ says IOB’s
founder and director Akhilesh Pandey,
M.D., Ph.D., who is also a researcher at
Johns Hopkins University School of Medi-
cine. ‘‘And we accomplish them in a time
frame that would be virtually unthinkable
elsewhere.’’
This is not a vain boast. Take, for
instance, the Institute’s Human Protein
Reference Database, an unprecedented
online compendium of curated protein
information. Containing information about
more than 27,000 proteins and 39,000
protein-protein interactions, the database
is the fruit of several years of effort from
curators who sifted through more than
2,000,000 research papers. Unlike mostother protein databases, IOB’s creation
encapsulates virtually every relevant fea-
ture of each protein—function, sequence,
domains, motifs, interactions, expression,
localization, modifications, disease asso-
ciations—and includes results obtained
with almost any experimental platform.
Initiated in 2003, this resource is now in
wide use: among its many clients are the
biological network visualization tool Cere-
bral, the sequence analysis tool Compar-
iMotif, and the type 1 diabetes research
database T1Dbase. The website that
hosts this resource now gets millions of
hits each month. The database is also
the scaffold for the institute’s Proteinpe-
dia, a unique repository of contributedproteomic datasets that includes nearly
two million peptides from about 2,700
experiments from 75 laboratories world-
wide. Proteinpedia too has become a
valuable resource for proteomics. ‘‘Re-
searchers across the world recognize
and appreciate us as human protein data-
base people,’’ says Keshava Prasad,
Ph.D., an IOB faculty scientist who coor-
dinates this database today.
Pandey conceived the idea of a Banga-
lore-based bioinformatics institute nearly
a decade ago. A proteomics researcher,
Pandey was an early adopter of high-
throughput techniques such as mass
spectrometry. In fact, as a visiting scien-
tist at Matthias Mann’s laboratory, then
at the University of Southern Denmark,
he developed SILAC (Stable Isotope
Labeling with Amino acids in Cell culture),
a revolutionary technique to observe a
cell’s changing proteome. The problem
with such techniques, Pandey observed,
was that interpreting the vast amount of
data they generate needs a large team
of biologists skilled in computationalChemistry & Biology 17, March 26, 2010methods. In the U.S., finding such a
team can be very hard and funding
them, even harder; ‘‘That’s when I thought
of Bangalore,’’ says Pandey. An institute
based there could recruit and train biolo-
gists to excel in the painstaking, intensive,
and often laborious tasks that high-
throughput proteomics requires.
Most of Pandey’s friends and
colleagues thought the idea was crazy.
Even those who saw merit in it, such
as Pandey’s erstwhile mentor Mann,
wondered, ‘‘But where is the money?’’
But such skepticism only served to
make Pandey even more determined. By
spending all his savings, then borrowing
to the limit of his credits cards and finally
borrowing from his brother, Pandey
managed to get IOB up and running in
December 2002. ‘‘When everyone op-
poses you, the chances are you are doing
something right,’’ Pandey jokes. It wasn’t
until much later that grants from various
U.S. and Indian sources helped ease the
funding pressure.
That was only one part of the institute’s
struggle. ‘‘Now we are seeing the good
times, but we’ve had to come a long
way,’’ recalls Harsha Gowda, Ph.D., who
joined the institute soon after its inception
in 2002. At that time, apart from dealing
with equipment, infrastructure, and staff-
ing issues, IOBhad to struggle to establish
its reputation. As a research start-up, it
hadno track record yet; its unconventional
structure as a privately funded research
institute made it a hard sell in the eyes of
funding agencies. The turning point
came when some of its initial research
efforts culminated in prestigious publica-
tions. One of these was the annotation of
the human X chromosome. At that time,
the lab that sequenced the chromosome
was engaged in a similar effort. ‘‘As
a small, non-sequencing center, we were
fighting against the odds,’’ says Gowda.
Nonetheless, both efforts were rewarded
with papers in the April 2005 issue of
Nature Genetics, accompanied by anª2010 Elsevier Ltd All rights reserved 207
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as ‘‘a featworth replicating.’’ Asa research
institute, IOB had ‘‘arrived.’’ A string of
other publications on protein databases,
cancer biomarkers, and other topics
consolidated its reputation. Grant money
flowed in more readily. ‘‘In fact, we have
had 100% success in the past few grants
we’ve applied for,’’ says Gowda. ‘‘Now
IOB is accepted as one of the premier
research institutes in India.’’
Proteogenomics, the use of proteomics
to annotate genes, is an area in which IOB
has carved out a niche for itself. The moti-
vation is simple: genome sequencing has
become increasingly faster and cheaper,
but genome annotation—identifying and
characterizing genes—has lagged behind.
Given a nucleotide sequence, researchers
typically rely on algorithms that predict
genes either directly or by homology with
known genes from similar organisms.
Neither method is foolproof. Most existing
genomeannotations are riddledwith errors
such as missing, split, or truncated genes;
wrong start codons or wrong N termini;
and short, noncoding regions mistaken for
true genes—so much so that almost half
the genes in a typical genome annotation
are labeled as ‘‘hypothetical’’ unless
confirmed by other methods. ‘‘To annotate
genes reliably, you must understand the
three ’omes’: genome, transcriptome, and
proteome, and you should have the instru-
mentation, the bioinformatics capability,
and the inclination for it,’’ says Pandey.
‘‘At thispoint in time, there’sonly IOBwhich
can pull it off.’’
IOB’s work on the malaria-carrying
Anopheles gambiae mosquito demon-
strates the utility of its approach. The ex-
isting genome annotation listed about
13,000 genes. By carrying out a proteomic
analysis of certain organs of the insect,
IOB researchers identified 8,675 unique
peptides. Of these, 94 lay inside introns,
5 lay in UTRs, 12 overlapped intron-exon
junction, 42 lay near mapped genes, and
so on: in total, such anomalies helped
correct nearly 200 gene annotations.208 Chemistry & Biology 17, March 26, 2010‘‘The most thrilling part was that we iden-
tified and validated around 35 novel
genes,’’ says Sutopa Dwivedi, a doctoral
student who plans to annotate the related
A. stephensi mosquito next.
Other IOB candidates in various stages
of proteogenomic annotation include the
leishmania parasite; the tuberculosis
bacterium; E. coli; the tomato, mango,
silkworm, basil, and neem plants; and
several species of yeast. Pandey hopes
to expand these efforts and establish a
center of proteogenomics that will be a
first of its kind in the world. ‘‘We believe
that in the future, when scientists se-
quence a new genome, they will also
sequence its proteome and then put out
the data in the community,’’ says Pandey.
‘‘This will become the only acceptable
way to do things.’’
Another ambitious ongoing project at
IOB is NetPath, a curated database of
human signaling and metabolic pathway
information. A vast amount of information
about cellular signaling events is available
in the literature. A database that collects
and organizes this widely scattered infor-
mation in the form of pathways would be
of immense value to systems biology
studies. This task, however, is complex,
intensive, laborious, and can’t be auto-
mated; as a result, the pathway resources
that exist have many limitations and none
are fully curated. As with the human
protein reference database and other
large-scale curated resources, IOB has
again stepped forward to build a ‘‘one-
stop shop’’ for human pathways. Several
university students are being trained to
work alongside IOB researchers to
complete this mammoth task, says Ku-
maran Kandasamy, who leads the cura-
tion effort. A preliminary version is already
up and running, with 10 immune signaling
pathways; IOB hopes to expand it to
about 500 signaling and 500 metabolic
pathways. ‘‘We have a clear goal in the
coming three years: to become the
number one source of all pathway infor-
mation in humans,’’ declares Pandey.ª2010 Elsevier Ltd All rights reservedWhile pursuing this and other ambitious
goals, IOB has to deal with many chal-
lenges. Pandey may no longer need to
max out his credit card to pay the insti-
tute’s bills, but funding remains a concern.
The institute’s annual running cost of
about $350,000, though small by U.S.
standards, is still a considerable amount.
Generous grants from various Indian
funding agencies notwithstanding, Pan-
dey and colleagues can’t afford to spend
too lavishly. For instance, ‘‘although we
have state-of-the art equipment, we
can’t yet afford a cold room,’’ says Pan-
dey, pointing to the refrigerators that
now serve the purpose. Many conve-
niences taken for granted in the West
are harder to obtain in a third-world
country. Key reagents may take several
weeks to arrive after ordering; this
precludes a trial-and-error approach to
find the best pipelines for various types
of experiments. ‘‘We can’t afford to play
around too much here,’’ says Pandey.
‘‘That’s why we prefer to work with well-
established pipelines.’’ Although infra-
structure issues have been minimized,
some remain. Equipment failure is a po-
tential concern, as replacement parts
may be hard to find. Internet speeds in
India remain modest compared to the
West; IOB’s protein databases are hosted
on U.S. servers to ensure a fast response.
Despite these challenges, IOB’s rise as
a proteomics research center has been
nothing short of meteoric. Armed with
the equipment, manpower, skills, andwill-
ingness to take on large-scale proteomics
projects, this tiny Bangalore institute is
now poised to ‘‘play with the big boys,’’
says Pandey. Indeed, so pleased is he
with its success in proteogenomics that
he is considering setting up a similar
center in the U.S.. ‘‘An Indian institute
becoming a model for the West, that
would have been unthinkable before,’’
he says. ‘‘But we are beginning to perma-
nently change the way things are done.’’
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